Medical device producer Oscor has led the heart disease treatment system developer's $20m series D round in connection with a strategic partnership.

Gyroscope Therapeutics recently commenced phase 1/2 clinical trials on a retinal gene therapy for dry age-related macular degeneration.

The seed capital will help UAB-founded TriAltus Bioscience commercialise its protein purification materials, which are already being used by research clients in the US, Brazil and EU.

Abiomed-backed Shockwave Medical has raised approximately $97m in an oversubscribed initial public offering, before its shares climbed more than 85% by the end of Friday.

Anaveon emerged out of University of Zurich in late 2017 with the support of Novartis-backed UZH Life Sciences Fund and the corporate has now also invested directly.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Rabobank has contributed to Gilde Healthcare’s third private equity fund, which will focus on established and profitable businesses in the Benelux and Dach countries.

Oregon Venture Fund and Rogue Venture Partners have both backed University of Oregon's DNA testing services provider NemaMetrix to bring the spinout’s total to $8.5m.

Health for Life Capital II has achieved its first close thanks to commitments from strategic partners Danone, Novartis, Lesaffre, Wright Medical, Unicéréales and Bel.

GV participated as a new investor, as Harvard's genetic medicine developer Beam Therapeutics completed a round that followed $87m in series A funding last year.